000			nab a22 7a 4500
999			_c16694 _d16694
003			pc16694
005			20211217125429.0
008			211217b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_9811 _aRuiz Contreras, Jesús _ePediatría
245	0	0	_aVacunación frente al meningococo B. Posicionamiento del Comité Asesor de Vacunas de la Asociación Española de Pediatría. _h[guía clínica]
260			_bAnales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.). _c2014
300			_a198.e1-9.
500			_aFormato Vancouver: Moreno Pérez D, Álvarez García FJ, Arístegui Fernández J, Cilleruelo Ortega MJ, Corretger Rauet JM, García Sánchez N et al; Comité Asesor de Vacunas de la Asociación Española de Pediatría. Vacunación frente al meningococo B. Posicionamiento del Comité Asesor de Vacunas de la Asociación Española de Pediatría. An Pediatr (Barc). 2015 Mar;82(3):198.e1-9.
501			_aPMID: 25304451
504			_aContiene 30 referencias
520			_aMeningococcal invasive disease, including the main clinical presentation forms (sepsis and meningitis), is a severe and potentially lethal infection caused by different serogroups of Neisseria meningitidis. Meningococcal serogroup B is the most prevalent in Europe. Most cases occur in children, with a mortality rate of 10% and a risk of permanent sequelae of 20-30% among survivors. The highest incidence and case fatality rates are observed in healthy children under 2-3 years old, followed by adolescents, although it can occur at any age. With the arrival in Spain of the only available vaccine against meningococcus B, the Advisory Committee on Vaccines of the Spanish Association of Paediatrics has analysed its preventive potential in detail, as well as its peculiar administrative situation in Spain. The purpose of this document is to publish the statement of the Committee as regards this vaccination and the access to it by the Spanish population, taking into account that it has been only authorized for people at risk. The vaccine is available free in the rest of Europe for those who want to acquire it, and in some countries and regions it has been introduced into the systematic immunisation schedules. The Committee considers that Bexsero® has a profile of a vaccine to be included in the official schedules of all the Spanish autonomous communities and insists on the need for it to be available in pharmacies for its administration in all children older than 2 months.
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16694.pdf _ySolicitar documento
942			_2ddc _cGUI _n0